Health Condition 1: K77- Liver disorders in diseases classified elsewhere
Conditions
Interventions
None listed
Sponsors
Dr Santosh Kumar Thakur
Eligibility
Inclusion criteria
Inclusion criteria: Elevated AST and ALT levels >40 IU/L Voluntary Participation in randomized design.
Exclusion criteria
Exclusion criteria: Patients will not be included in the study if, a. Patient with hepatocellular carcinoma, cirrhosis, fulminant hepatitis, obstructive jaundice, autoimmune diseases b. Any other serious disease limiting life expectancy. c.Pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The trial aims to determine if the studied drugs might be efficacious and safe in the treatment of liver disorders. This will help in developing clinical management guidelines for Liver disorder management as well as to develop policy related to treatment and management. Efficacy Endpoints Primary endpoint: Improvement in the investigational assessment AST and ALT levels of the blood. Key Secondary endpoint: Quality of life of the patient.Timepoint: 8 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Key Secondary endpoint: Quality of life of the patient.Timepoint: Two Years | — |
Countries
Nepal
Contacts
Public ContactSantosh Kumar Thakur
National Institute of Ayurveda Deemed to be University (De Novo)
Outcome results
None listed